126
Views
24
CrossRef citations to date
0
Altmetric
Original Article

Characterisation of [3H]-Darifenacin as a Novel Radioligand for the Study of Muscarinic M3 Receptors

&
Pages 177-184 | Published online: 26 Jun 2009

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Norman, Zinner. (2007) Darifenacin: a muscarinic M3-selective receptor antagonist for the treatment of overactive bladder. Expert Opinion on Pharmacotherapy 8:4, pages 511-523.
Read now

Articles from other publishers (23)

Johannes Köckenberger, Oliver Fischer, Andreas Konopa, Sebastian Bergwinkl, Susanne Mühlich, Peter Gmeiner, Roger Jan Kutta, Harald Hübner, Max Keller & Markus R. Heinrich. (2022) Synthesis, Characterization, and Application of Muscarinergic M 3 Receptor Ligands Linked to Fluorescent Dyes . Journal of Medicinal Chemistry 65:24, pages 16494-16509.
Crossref
Alexander I. Chernyavsky, Valentin Galitovskiy & Sergei A. Grando. (2015) Molecular mechanisms of synergy of corneal muscarinic and nicotinic acetylcholine receptors in upregulation of E-cadherin expression. International Immunopharmacology 29:1, pages 15-20.
Crossref
Stephen P.H. Alexander, Helen E. Benson, Elena Faccenda, Adam J. Pawson, Joanna L. Sharman, Michael Spedding, John A. Peters & Anthony J. Harmar. (2013) The Concise Guide to PHARMACOLOGY 2013/14: G Protein-Coupled Receptors. British Journal of Pharmacology 170:8, pages 1459-1581.
Crossref
G. G. Kay & U. Ebinger. (2008) Preserving cognitive function for patients with overactive bladder: evidence for a differential effect with darifenacin. International Journal of Clinical Practice 62:11, pages 1792-1800.
Crossref
Kyu-Sung LeeYoung-Suk Lee. (2007) Overactive Bladder. Korean Journal of Urology 48:12, pages 1191.
Crossref
Phillip P Smith, H Henry Lai & Rodney A Appell. (2006) Darifenacin: a selective M 3 muscarinic receptor antagonist for the treatment of overactive bladder . Therapy 3:6, pages 723-732.
Crossref
William D. Steers. (2006) Darifenacin: Pharmacology and Clinical Usage. Urologic Clinics of North America 33:4, pages 475-482.
Crossref
David R. P. Guay. (2005) Darifenacin: Another Antimuscarinic for Overactive Bladder. The Consultant Pharmacist 20:5, pages 424-431.
Crossref
Gamal Ghoniem & John Hairston. 2004. Female Urology, Urogynecology, and Voiding Dysfunction. Female Urology, Urogynecology, and Voiding Dysfunction 23 43 .
Zhiguo Wang, Hong Shi & Huizhen Wang. (2004) Functional M 3 muscarinic acetylcholine receptors in mammalian hearts . British Journal of Pharmacology 142:3, pages 395-408.
Crossref
Thomas Kerbusch, Peter A. Milligan & Mats O. Karlsson. (2003) Assessment of the relative in vivo potency of the hydroxylated metabolite of darifenacin in its ability to decrease salivary flow using pooled population pharmacokinetic-pharmacodynamic data. British Journal of Clinical Pharmacology 57:2, pages 170-180.
Crossref
Helena F Wrzos. (2004) Mechanisms mediating cholinergic antral circular smooth muscle contraction in rats. World Journal of Gastroenterology 10:22, pages 3292.
Crossref
Katherine F Croom & Gillian M Keating. (2004) Darifenacin. Drugs & Aging 21:13, pages 885-892.
Crossref
Thomas Kerbusch, Ulrika Wählby, Peter A. Milligan & Mats O. Karlsson. (2003) Population pharmacokinetic modelling of darifenacin and its hydroxylated metabolite using pooled data, incorporating saturable first-pass metabolism, CYP2D6 genotype and formulation-dependent bioavailability . British Journal of Clinical Pharmacology 56:6, pages 639-652.
Crossref
NAOKI YOSHIMURA & MICHAEL B. CHANCELLOR. (2002) Current and Future Pharmacological Treatment for Overactive Bladder. The Journal of Urology, pages 1897-1913.
Crossref
NAOKI YOSHIMURA & MICHAEL B. CHANCELLOR. (2002) Current and Future Pharmacological Treatment for Overactive Bladder. Journal of Urology 168:5, pages 1897-1913.
Crossref
William C de GroatNaoki Yoshimura. (2001) Pharmacology of the Lower Urinary Tract. Annual Review of Pharmacology and Toxicology 41:1, pages 691-721.
Crossref
A Choppin & R M Eglen. (2001) Pharmacological characterization of muscarinic receptors in dog isolated ciliary and urinary bladder smooth muscle. British Journal of Pharmacology 132:4, pages 835-842.
Crossref
Naoki Yoshimura, Christopher P. Smith, Michael B. Chancellor & William C. de Groat. (2000) Pharmacologic and potential biologic interventions to restore bladder function after spinal cord injury. Current Opinion in Neurology 13:6, pages 677-681.
Crossref
Christian C. Felder, Frank P. Bymaster, John Ward & Neil DeLapp. (2000) Therapeutic Opportunities for Muscarinic Receptors in the Central Nervous System. Journal of Medicinal Chemistry 43:23, pages 4333-4353.
Crossref
CHRISTOPHER R. CHAPPLE. (2014) MUSCARINIC RECEPTOR ANTAGONISTS IN THE TREATMENT OF OVERACTIVE BLADDER. BJU International 85:S3, pages 33-46.
Crossref
Christopher R Chapple. (2000) Muscarinic receptor antagonists in the treatment of overactive bladder. Urology 55:5, pages 33-46.
Crossref
Robert M. Wallis & Carolyn M. Napier. (1999) Muscarinic antagonists in development for disorders of smooth muscle function. Life Sciences 64:6-7, pages 395-401.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.